NCT02165761

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: W.L.Gore & Associates · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To characterize the GORE® Hybrid Vascular Graft as compared to non-heparin bonded synthetic vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 / heparin antibodies (anti-PF4 / H antibodies).

Conditions

• End Stage Renal Disease

Interventions

Type	Name	Description
DEVICE	GORE® Hybrid Vascular Graft
DEVICE	Non-heparin bonded synthetic graft

Timeline

• Start date: 2014-07-01
• Primary completion: 2017-01-20
• Completion: 2017-01-20
• First posted: 2014-06-17
• Last updated: 2018-02-19
• Results posted: 2018-02-19

Locations

4 sites across 1 country: United States